Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers

Dirk Rades, Daniel Seidl, Stefan Janssen, Primoz Strojan, Katarina Karner, Amira Bajrovic, Samer G. Hakim, Barbara Wollenberg, Steven E. Schild

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Radio-chemotherapy is a common treatment for locally advanced squamous cell head-and-neck cancers (LA-SCCHN). Cisplatin (100 mg/m2) every 3 weeks is very common but associated with considerable toxicity. Therefore, cisplatin programs with lower daily doses were introduced. There is a lack of studies comparing lower-dose programs. In this study, 85 patients receiving radio-chemotherapy with 20 mg/m2 cisplatin on 5 days every 4 weeks (group A) were retrospectively compared to 85 patients receiving radio-chemotherapy with 30–40 mg/m2 cisplatin weekly (group B). Groups were matched for nine factors including age, gender, performance score, tumor site, T-/N-category, surgery, hemoglobin before radio-chemotherapy, and radiation technique. One- and 3-year loco-regional control rates were 83 and 69 % in group A versus 74 and 63 % in group B (p = 0.12). One- and 3-year survival rates were 93 % and 73 % in group A versus 91 and 49 % in group B (p = 0.011). On multivariate analysis, survival was significantly better for group A (HR 1.17; p = 0.002). In groups A and B, 12 and 28 % of patients, respectively, did not receive a cumulative cisplatin dose ≥180 mg/m2 (p = 0.016). Toxicity rates were not significantly different. On subgroup analyses, group A patients had better loco-regional control (p = 0.040) and survival (p = 0.005) than group B patients after definitive radio-chemotherapy. In patients receiving adjuvant radio-chemotherapy, outcomes were not significantly different. Thus, 20 mg/m2 cisplatin on 5 days every 4 weeks resulted in better loco-regional control and survival in patients receiving definitive radio-chemotherapy and may be preferable for these patients. Confirmation of these results in a randomized trial is warranted.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalEuropean Archives of Oto-Rhino-Laryngology
DOIs
StateAccepted/In press - Sep 29 2016

Fingerprint

Head and Neck Neoplasms
Radio
Cisplatin
Drug Therapy
Survival
Squamous Cell Neoplasms
Age Factors
Adjuvant Chemotherapy
Hemoglobins
Research Design
Multivariate Analysis
Survival Rate
Radiation
Neoplasms

Keywords

  • LA-SCCHN
  • Loco-regional control
  • Lower-dose cisplatin
  • Radio-chemotherapy
  • Survival
  • Toxicity

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. / Rades, Dirk; Seidl, Daniel; Janssen, Stefan; Strojan, Primoz; Karner, Katarina; Bajrovic, Amira; Hakim, Samer G.; Wollenberg, Barbara; Schild, Steven E.

In: European Archives of Oto-Rhino-Laryngology, 29.09.2016, p. 1-7.

Research output: Contribution to journalArticle

Rades, Dirk ; Seidl, Daniel ; Janssen, Stefan ; Strojan, Primoz ; Karner, Katarina ; Bajrovic, Amira ; Hakim, Samer G. ; Wollenberg, Barbara ; Schild, Steven E. / Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. In: European Archives of Oto-Rhino-Laryngology. 2016 ; pp. 1-7.
@article{0b9eda463e844bfb93ba4ced2aa9ce2f,
title = "Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers",
abstract = "Radio-chemotherapy is a common treatment for locally advanced squamous cell head-and-neck cancers (LA-SCCHN). Cisplatin (100 mg/m2) every 3 weeks is very common but associated with considerable toxicity. Therefore, cisplatin programs with lower daily doses were introduced. There is a lack of studies comparing lower-dose programs. In this study, 85 patients receiving radio-chemotherapy with 20 mg/m2 cisplatin on 5 days every 4 weeks (group A) were retrospectively compared to 85 patients receiving radio-chemotherapy with 30–40 mg/m2 cisplatin weekly (group B). Groups were matched for nine factors including age, gender, performance score, tumor site, T-/N-category, surgery, hemoglobin before radio-chemotherapy, and radiation technique. One- and 3-year loco-regional control rates were 83 and 69 {\%} in group A versus 74 and 63 {\%} in group B (p = 0.12). One- and 3-year survival rates were 93 {\%} and 73 {\%} in group A versus 91 and 49 {\%} in group B (p = 0.011). On multivariate analysis, survival was significantly better for group A (HR 1.17; p = 0.002). In groups A and B, 12 and 28 {\%} of patients, respectively, did not receive a cumulative cisplatin dose ≥180 mg/m2 (p = 0.016). Toxicity rates were not significantly different. On subgroup analyses, group A patients had better loco-regional control (p = 0.040) and survival (p = 0.005) than group B patients after definitive radio-chemotherapy. In patients receiving adjuvant radio-chemotherapy, outcomes were not significantly different. Thus, 20 mg/m2 cisplatin on 5 days every 4 weeks resulted in better loco-regional control and survival in patients receiving definitive radio-chemotherapy and may be preferable for these patients. Confirmation of these results in a randomized trial is warranted.",
keywords = "LA-SCCHN, Loco-regional control, Lower-dose cisplatin, Radio-chemotherapy, Survival, Toxicity",
author = "Dirk Rades and Daniel Seidl and Stefan Janssen and Primoz Strojan and Katarina Karner and Amira Bajrovic and Hakim, {Samer G.} and Barbara Wollenberg and Schild, {Steven E.}",
year = "2016",
month = "9",
day = "29",
doi = "10.1007/s00405-016-4326-5",
language = "English (US)",
pages = "1--7",
journal = "European Archives of Oto-Rhino-Laryngology",
issn = "0937-4477",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers

AU - Rades, Dirk

AU - Seidl, Daniel

AU - Janssen, Stefan

AU - Strojan, Primoz

AU - Karner, Katarina

AU - Bajrovic, Amira

AU - Hakim, Samer G.

AU - Wollenberg, Barbara

AU - Schild, Steven E.

PY - 2016/9/29

Y1 - 2016/9/29

N2 - Radio-chemotherapy is a common treatment for locally advanced squamous cell head-and-neck cancers (LA-SCCHN). Cisplatin (100 mg/m2) every 3 weeks is very common but associated with considerable toxicity. Therefore, cisplatin programs with lower daily doses were introduced. There is a lack of studies comparing lower-dose programs. In this study, 85 patients receiving radio-chemotherapy with 20 mg/m2 cisplatin on 5 days every 4 weeks (group A) were retrospectively compared to 85 patients receiving radio-chemotherapy with 30–40 mg/m2 cisplatin weekly (group B). Groups were matched for nine factors including age, gender, performance score, tumor site, T-/N-category, surgery, hemoglobin before radio-chemotherapy, and radiation technique. One- and 3-year loco-regional control rates were 83 and 69 % in group A versus 74 and 63 % in group B (p = 0.12). One- and 3-year survival rates were 93 % and 73 % in group A versus 91 and 49 % in group B (p = 0.011). On multivariate analysis, survival was significantly better for group A (HR 1.17; p = 0.002). In groups A and B, 12 and 28 % of patients, respectively, did not receive a cumulative cisplatin dose ≥180 mg/m2 (p = 0.016). Toxicity rates were not significantly different. On subgroup analyses, group A patients had better loco-regional control (p = 0.040) and survival (p = 0.005) than group B patients after definitive radio-chemotherapy. In patients receiving adjuvant radio-chemotherapy, outcomes were not significantly different. Thus, 20 mg/m2 cisplatin on 5 days every 4 weeks resulted in better loco-regional control and survival in patients receiving definitive radio-chemotherapy and may be preferable for these patients. Confirmation of these results in a randomized trial is warranted.

AB - Radio-chemotherapy is a common treatment for locally advanced squamous cell head-and-neck cancers (LA-SCCHN). Cisplatin (100 mg/m2) every 3 weeks is very common but associated with considerable toxicity. Therefore, cisplatin programs with lower daily doses were introduced. There is a lack of studies comparing lower-dose programs. In this study, 85 patients receiving radio-chemotherapy with 20 mg/m2 cisplatin on 5 days every 4 weeks (group A) were retrospectively compared to 85 patients receiving radio-chemotherapy with 30–40 mg/m2 cisplatin weekly (group B). Groups were matched for nine factors including age, gender, performance score, tumor site, T-/N-category, surgery, hemoglobin before radio-chemotherapy, and radiation technique. One- and 3-year loco-regional control rates were 83 and 69 % in group A versus 74 and 63 % in group B (p = 0.12). One- and 3-year survival rates were 93 % and 73 % in group A versus 91 and 49 % in group B (p = 0.011). On multivariate analysis, survival was significantly better for group A (HR 1.17; p = 0.002). In groups A and B, 12 and 28 % of patients, respectively, did not receive a cumulative cisplatin dose ≥180 mg/m2 (p = 0.016). Toxicity rates were not significantly different. On subgroup analyses, group A patients had better loco-regional control (p = 0.040) and survival (p = 0.005) than group B patients after definitive radio-chemotherapy. In patients receiving adjuvant radio-chemotherapy, outcomes were not significantly different. Thus, 20 mg/m2 cisplatin on 5 days every 4 weeks resulted in better loco-regional control and survival in patients receiving definitive radio-chemotherapy and may be preferable for these patients. Confirmation of these results in a randomized trial is warranted.

KW - LA-SCCHN

KW - Loco-regional control

KW - Lower-dose cisplatin

KW - Radio-chemotherapy

KW - Survival

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84989172162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989172162&partnerID=8YFLogxK

U2 - 10.1007/s00405-016-4326-5

DO - 10.1007/s00405-016-4326-5

M3 - Article

C2 - 27687678

AN - SCOPUS:84989172162

SP - 1

EP - 7

JO - European Archives of Oto-Rhino-Laryngology

JF - European Archives of Oto-Rhino-Laryngology

SN - 0937-4477

ER -